How is orforglipron taken?

Label strengths and dose steps
StepTablet strengthTime on it before the next step
Start0.8 mg once daily1At least 30 days
Second2.5 mg once daily1At least 30 days
Third5.5 mg once daily1At least 30 days
Next levels, if increased9 mg, then 14.5 mg1At least 30 days on the current dosage, based on treatment response and tolerability
Maximum17.2 mg once daily1Not applicable

The US label for Foundayo (orforglipron) tablets, in adults with obesity or adults with overweight and at least one weight-related comorbid condition, starts at 0.8 mg orally once daily and steps to 2.5 mg and then 5.5 mg after at least 30 days on each; the dosage may then be increased to 9 mg, 14.5 mg or 17.2 mg once daily after at least 30 days on the current dosage, based on treatment response and tolerability, to a maximum of 17.2 mg once daily.1

Label strengths and dose steps

The table is set at the top of the page

The label lists Foundayo as tablets in six strengths, from 0.8 mg to 17.2 mg, in bottles of 30.1 Tablets are swallowed whole, not broken, crushed or chewed, and the administration instructions have no mixing or reconstitution step.1 Searches of DailyMed (Foundayo tablets only), PubMed, the EMA news page and ClinicalTrials.gov (a partial list, all tablet or capsule by mouth) found no powder, vial, injectable or compounded form of orforglipron and no stability data after mixing, so there is no dose-to-syringe conversion to give.

Schedule, food and missed doses

The label says Foundayo is taken once daily, with or without food.1 The label also says not to take more than one tablet per day.1 The EMA's 16 October 2026 news item on the CHMP's recommendation, which goes to the European Commission for a decision, says it can be taken at any time of day, and that treatment starts at a low dose which is gradually increased according to the patient’s response and how well they tolerate the medicine.2 If a dose is missed, the label says to take it as soon as possible and not to double up.1 After 7 or more consecutive missed doses, the label says escalation is reinitiated at a lower dosage.1

Doses used in the trials

The label's 72-week weight-management trials, one in 3,127 adults (3:3:3:4) and one in 1,613 adults (1:1:1:2), randomised patients to 5.5 mg, 9 mg or 17.2 mg once daily or placebo, with dosages titrated by the label's escalation.1 The label says its trials used an investigational orforglipron formulation and shows their data as equivalent dosages of once daily Foundayo;1 the ACHIEVE-1 registry entry describes orforglipron capsules,3 and the trial papers give their doses in milligram figures that differ from the label strengths.

TrialDose and schedulePeopleLength
ATTAIN-1 (Wharton, 2025)6, 12 or 36 mg or placebo once daily, assigned 3:3:3:443127 adults with obesity and no diabetes472 weeks4
ATTAIN-2 (Horn, 2026)6, 12 or 36 mg or placebo once daily, assigned 1:1:1:251613 adults with obesity or overweight (BMI of 27 kg/m2 or higher) and type 2 diabetes, HbA1c 7-10%572 weeks5
ACHIEVE-1 (Rosenstock, 2025)3, 12 or 36 mg or placebo once daily, assigned 1:1:1:16559 adults with early type 2 diabetes treated only with diet and exercise640 weeks6
Phase 2, obesity (Wharton, 2023)12, 24, 36 or 45 mg or placebo once daily7272 adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes736 weeks7
Phase 2, type 2 diabetes (Frias, 2023)3 mg, 12 mg, 24 mg, 36 mg or 45 mg once per day with no food or water restrictions, with two escalation regimens for each of the 36 mg and 45 mg cohorts, against placebo or dulaglutide 1·5 mg once per week8383 adults with type 2 diabetes treated with diet and exercise, with or without metformin826 weeks8

The ATTAIN-1 registry entry says each arm started at 1 mg and escalated every 4 weeks to its target dose.9 A phase 1 bioequivalence study (Ma, 2026) in 429 healthy adults with obesity or overweight gave each dose strength once daily for 7 days in the fasted state at capsule doses of 1, 3, 6, 12, 24, or 36 mg and corresponding tablet doses of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg, and reported the two bioequivalent across all six doses.10

Storage

The label says to store Foundayo at room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).1

Frequently asked questions

Does orforglipron have on and off cycles?

The label's dosing section gives no on/off cycle; its trial safety pool treated patients once daily for up to 72 weeks, then followed them for 2 weeks off the drug.1

Can orforglipron be combined with another GLP-1 drug?

The label's limitation of use says taking Foundayo with another GLP-1 receptor agonist is not recommended.1

References

  1. Eli Lilly and Company (DailyMed). These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial U.S. Approval: 2026. 2026. dailymed.nlm.nih.gov
  2. European Medicines Agency. New oral GLP-1 medicine for weight management and type 2 diabetes | European Medicines Agency (EMA). 2026. ema.europa.eu
  3. ClinicalTrials.gov. NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone. 2026. clinicaltrials.gov
  4. PubMed. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. 2025. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. 2026. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. 2025. pubmed.ncbi.nlm.nih.gov
  7. PubMed. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. 2023. pubmed.ncbi.nlm.nih.gov
  8. PubMed. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. 2023. pubmed.ncbi.nlm.nih.gov
  9. ClinicalTrials.gov. NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities. 2026. clinicaltrials.gov
  10. PubMed. Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. 2026. pubmed.ncbi.nlm.nih.gov